TransMedics Secures FDA IDE Approval for 650-Patient OCS ENHANCE Heart Trial
TransMedics won full FDA IDE approval for its next-generation OCS ENHANCE Heart trial, enabling patient enrollment in a two-part study of over 650 donors comparing extended perfusion versus cold storage. The approval de-risks its clinical roadmap and bolsters prospects for expanded OCS Heart adoption and recurring disposables revenue.
1. FDA Approval Details
TransMedics received full, unconditional FDA IDE approval for its next-generation OCS ENHANCE Heart trial, removing a key regulatory milestone and authorizing patient recruitment and full trial execution.
2. Trial Design
The ENHANCE trial is a two-part program enrolling over 650 donors to evaluate prolonged heart perfusion with the OCS Heart system in part A and compare clinical outcomes against traditional static cold storage in part B.
3. Market and Commercial Impact
This approval de-risks TransMedics’ clinical roadmap, supports potential label expansion and broader adoption of the OCS platform, and could drive recurring disposables revenue by extending preservation windows and increasing utilization per transplant center.